Connect Biopharma Holdings Limited
CNTBHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeConnect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. The company carries a $115.9M market cap, placing it firmly in the micro-cap category. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
Market Cap
$115.9M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-2.47
EPS (TTM)
$-1.19
EPS (Fwd)
$-0.75
ROE
-140.5%
ROA
-69.8%
Cash
$31.5M
Total Debt
$596,000
Free CF
-$34.7M
52W Change
4.5%
Annual Financials
Cash vs Debt
Where CNTB stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CNTB finished 11.74% above its 150-day moving average ($2.47) and 11.29% above its 200-day moving average ($2.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CNTB overbought or oversold?
At the September 3, 2026 close, CNTB's RSI(14) was 57.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Connect Biopharma Holdings Limited holds $31.5M in cash against $596K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$34.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -140.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, CNTB has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Connect Biopharma Holdings Limited's trajectory.